Atefeh Ghahremanloo1,2, Arash Soltani1,2, Seyed Mohamad Sadegh Modaresi3, Seyed Isaac Hashemy4. 1. Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 2. Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 3. College of Pharmacy, University of Rhode Island, Kingston, RI, USA. 4. Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. hashemyi@mums.ac.ir.
Abstract
BACKGROUND: The discovery of immune checkpoint proteins and the mechanisms by which cancer cells utilize them to evade the immune system has transformed our approach to cancer immunotherapy. Checkpoint blockade antibodies targeting cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1) and its ligands such as programmed cell death ligand 1 (PD-L1) have already revolutionized the treatment of multiple types of cancer and have significantly improved treatment and survival outcomes of patients affected by these malignancies. CONCLUSIONS: Herein, we summarize current knowledge about the role of, and the mechanisms underlying PD-1/PD-L1 signaling pathways in antitumor immune responses, with particular emphasis on clinical studies evaluating the efficacy of anti-PD-1/PD-L1 blockade in various tumor types. Preliminary clinical investigations with immune-checkpoint blockers highlight broad opportunities with a high potential to enhance antitumor immunity and, as such, to generate significant clinical responses. These preliminary successes open up new avenues towards efficient therapeutics offered to patients.
BACKGROUND: The discovery of immune checkpoint proteins and the mechanisms by which cancer cells utilize them to evade the immune system has transformed our approach to cancer immunotherapy. Checkpoint blockade antibodies targeting cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1) and its ligands such as programmed cell death ligand 1 (PD-L1) have already revolutionized the treatment of multiple types of cancer and have significantly improved treatment and survival outcomes of patients affected by these malignancies. CONCLUSIONS: Herein, we summarize current knowledge about the role of, and the mechanisms underlying PD-1/PD-L1 signaling pathways in antitumor immune responses, with particular emphasis on clinical studies evaluating the efficacy of anti-PD-1/PD-L1 blockade in various tumor types. Preliminary clinical investigations with immune-checkpoint blockers highlight broad opportunities with a high potential to enhance antitumor immunity and, as such, to generate significant clinical responses. These preliminary successes open up new avenues towards efficient therapeutics offered to patients.
Authors: J O Ebinu; S L Stang; C Teixeira; D A Bottorff; J Hooton; P M Blumberg; M Barry; R C Bleakley; H L Ostergaard; J C Stone Journal: Blood Date: 2000-05-15 Impact factor: 22.113
Authors: Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman Journal: Nat Immunol Date: 2001-03 Impact factor: 25.606
Authors: Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen Journal: Nat Med Date: 2002-06-24 Impact factor: 53.440
Authors: G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo Journal: J Exp Med Date: 2000-10-02 Impact factor: 14.307
Authors: Mohammad Alomari; Suleiman Al Ashi; Pravallika Chadalavada; Shrouq Khazaaleh; Fahrettin Covut; Laith Al Momani; Ahmed Elkafrawy; Vinay Padbidri; Pauline Funchain; Donald Campbell; Carlos Romero-Marrero Journal: Gastroenterology Res Date: 2022-03-12
Authors: Niclas C Blessin; Patrick Spriestersbach; Wenchao Li; Tim Mandelkow; David Dum; Ronald Simon; Claudia Hube-Magg; Florian Lutz; Florian Viehweger; Maximillian Lennartz; Christoph Fraune; Vera Nickelsen; Wilfried Fehrle; Cosima Göbel; Sören Weidemann; Till Clauditz; Patrick Lebok; Katharina Möller; Stefan Steurer; Jacob R Izbicki; Guido Sauter; Sarah Minner; Frank Jacobsen; Andreas M Luebke; Franziska Büscheck; Doris Höflmayer; Waldemar Wilczak; Eike Burandt; Andrea Hinsch Journal: Cell Oncol (Dordr) Date: 2020-03-05 Impact factor: 6.730